Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (10/21/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage I, II, III, and IV CLL

Revised text to state that in the absence of randomized trials comparing the new B-cell receptor inhibitors and bcl-2 inhibitors to the new monoclonal antibodies and to more conventional chemotherapeutic agents, some general principles may provide a sequencing for available therapeutic options. Options were listed.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Key References for Chronic Lymphocytic Leukemia Treatment

Next section >
About This PDQ Summary